Pulmonary Arterial Hypertension Clinical Research Trials

Birmingham : The University of Alabama at Birmingham

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Birmingham : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Birmingham : Cardiovascular Associates, PC

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Birmingham : Cardiovascular Associates, P.C.

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Birmingham : The University of Alabama at Birmingham

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Mobile : University of South Alabama Medical Center

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Mobile : University of South Alabama

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Phoenix : Arizona Pulmonary Specialists, Ltd.

ACT-293987 in Pulmonary Arterial Hypertension

Phoenix : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Phoenix : Pulmonary Associates

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Phoenix : Arizona Pulmonary Specialists, LTD

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Tuscon : The University of Arizona, Clinical and Translational Science (CATS) Research Center

ACT-293987 in Pulmonary Arterial Hypertension

Berkeley : Alta Bates Summit Medical Center

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Berkeley : Berkeley Cardiovascular Medical Group

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Fountain Valley : Alliance Medical and Research Center

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Fresno : University California San Francisco

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Fresno : UCSF Fresno

Ventavis® Registry Protocol

La Jolla : University of California San Diego Medical Center (La Jolla)

ACT-293987 in Pulmonary Arterial Hypertension

La Jolla : UCSD Medical Center

Ventavis® Registry Protocol

Los Angeles : UCLA

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

Los Angeles : Cedars-Sinai Medical Center

ACT-293987 in Pulmonary Arterial Hypertension

Los Angeles : Ronald Reagan UCLA Medical Center

Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease

Los Angeles : UCLA Medical Center Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Los Angeles : University of Southern California

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Los Angeles : Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

Los Angeles : David Geffen School of Medicine UCLA

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

Los Angeles : David Geffen School of Medicine UCLA

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

Los Angeles : David Geffen School of Medicine, UCLA

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

Los Angeles : UCLA

Ventavis® Registry Protocol

Sacramento : University of California, Davis, UC Davis Medical Center

ACT-293987 in Pulmonary Arterial Hypertension

San Juan Capistrano : Paloma Medical Group

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

San Juan Capistrano : Paloma Medical Group

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Santa Barbara : Santa Barbara Cottage Hospital

Ventavis® Registry Protocol

Stanford : Stanford University Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Stanford : Stanford Hospital and Clinics

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Torrance : Los Angeles Biomedical Research Institute at Harbor-UCLA Med Ctr Updated

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Aurora : University of Colorado Denver Updated

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Aurora : The Children's Hospital - Site 9102

Pulmonary Arterial Hypertension in Children

Aurora : University of Colorado Denver

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Denver : National Jewish Medical and Research Center Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Denver : Children's Hospital Denver

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Littleton : South Denver Cardiology Associates PC

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Wheatridge : Robert E. Benkert, M.D.P.C.

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Wheatridge : Western States Clinical Research

Ventavis® Registry Protocol

New Haven : Yale University School of Medicine

Ventavis® Registry Protocol

Newark : Lung Health & Sleep Emhancement Center, LLC

ACT-293987 in Pulmonary Arterial Hypertension

Newark : Lung Health & Sleep Enhancement Center, LLC

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Clearwater : CRWF

Do you have Pulmonary Hypertension?

Do you have Chronic Obstructive Pulmonary Disease (COPD)?

Tampa : CRWF, Inc.

Do you have Pulmonary Hypertension?

Do you have Chronic Obstructive Pulmonary Disease (COPD)?

Brandon : Bay Area Cardiology Research, P.A.

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Clearwater : Bay Area Chest Physicians

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Clearwater : St. Francis Sleep Allergy & Lung

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Fort Lauderdale : Broward Pulmonary and Sleep Specialists

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Gainesville : University of Florida

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Gainesville : University of Florida

Ventavis® Registry Protocol

Jacksonville : University of Florida, Jacksonville

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

Miami Beach : Mount Sinai Medical Centre - Columbia University - Division of Cardiology

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Miami Beach : Mount Sinai Medical Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Orlando : Central Florida Pulmonary Group, PA

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Orlando : Central Florida Pulmonary Group, P.A.

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Orlando : Orlando Heart Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Orlando : Orlando Heart Center

Ventavis® Registry Protocol

Orlando : Central Florida Pulmonary Group

Ventavis® Registry Protocol

Sarasota : Lung Associates of Sarasota

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Weston : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Weston : Cleveland Clinic Florida

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Weston : Cleveland Clinic Florida

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Weston : Cleveland Cliic Florida

Ventavis® Registry Protocol

Atlanta : Emory University School of Medicine

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Augusta : Georgia Health Sciences University

ACT-293987 in Pulmonary Arterial Hypertension

Austell : Georgia Lung Associates, PC

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Chicago : University of Chicago

Assessmet of Patients With PAH Right Ventricular Volume

Chicago : Northwestern University Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Chicago : University of Chicago Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Chicago : University of Illinois at Chicago

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Chicago : Northwestern University

Ranolazine and Pulmonary Hypertension

Chicago : Northwestern Medical Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Oakbrook Terrace : Midwest Heart Foundation

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Carmel : Clarian North Hospital

ACT-293987 in Pulmonary Arterial Hypertension

Carmel : Indiana University Hospital

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Iowa City : University of Iowa Hospitals & Clinics

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Iowa City : University of Iowa

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Iowa City : Mercy Hospital

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Kansas City : University of Kansas Medical Center-Department of Pulmonary and Critical Care

ACT-293987 in Pulmonary Arterial Hypertension

Kansas City : University of Kansas Medical Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Kansas City : The University of Kansas Medical Center

Ventavis® Registry Protocol

Louisville : Kentuckiana Pulmonary Associates

ACT-293987 in Pulmonary Arterial Hypertension

Louisville : Kentuckiana Pulmonary Associates

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Louisville : Kentuckiana Pulmonary Associates

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Louisville : Kentuckiana Pulmonary Associates

Ventavis® Registry Protocol

New Orleans : LSU Health Science Center - New Orleans

ACT-293987 in Pulmonary Arterial Hypertension

New Orleans : Ochsner Clinic

Ventavis® Registry Protocol

Portland : Maine Medical Center

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Baltimore : Johns Hopkins University

A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis

Baltimore : Johns Hopkins University School of Medicine

ACT-293987 in Pulmonary Arterial Hypertension

Baltimore : John Hopkins University Medical Center Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Baltimore : Johns Hopkins University

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Baltimore : University of Maryland Medical Centre

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Baltimore : PAREXEL International Early Phase Clinical Unit - Baltimore

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

Baltimore : Johns Hopkins University

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Baltimore : University of Maryland

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Baltimore : University of Maryland School of Medicine

Ventavis® Registry Protocol

Boston : Boston University School of Medicine / Boston University Medical Center

ACT-293987 in Pulmonary Arterial Hypertension

Boston : Tufts Medical Center

ACT-293987 in Pulmonary Arterial Hypertension

Boston : Novartis Investigative Site

An Extension Study for Patients Who Participated in the CAMN107X2201 Study

Boston : Massachusetts General Hospital

Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan

Boston : Boston University Medical School Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Boston : Tufts Medical Center Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Boston : Brigham and Women's Hospital

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Boston : Tufts - New England Medical Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Worcester : University of Massachussetts Memorial Medical Center Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Ann Arbor : University of Michigan

ACT-293987 in Pulmonary Arterial Hypertension

Ann Arbor : University of Michigan Health System

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Ann Arbor : University of Michigan-Scleroderma Program Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Detroit : Henry Ford Hospital

ACT-293987 in Pulmonary Arterial Hypertension

Grand Rapids : Spectrum Health

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Troy : Beaumont Hospital

ACT-293987 in Pulmonary Arterial Hypertension

Troy : William Beaumont Hospital - Troy

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Troy : William Beaumont Hospital

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Minneapolis : Hennepin County Medical Center Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Minneapolis : University of Minnesota Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Rochester : Mayo Clinic

ACT-293987 in Pulmonary Arterial Hypertension

Rochester : Mayo Clinic

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Rochester : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Rochester : Mayo Clinic

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Chesterfield : CardioPulmonary Research Center at St. Lukes Hospital

ACT-293987 in Pulmonary Arterial Hypertension

St. Louis : Washington University School of Medicine

ACT-293987 in Pulmonary Arterial Hypertension

St. Louis : Washington University School of Medicine

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

St. Louis : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

St. Louis : St. Louis University

Ventavis® Registry Protocol

Lincoln : Nebraska Pulmonary Specialties, LLC

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Lincoln : Nebraska Pulmonary Specialties

Ventavis® Registry Protocol

Omaha : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Omaha : University of Nebraska Medical Center

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Omaha : Creighton University Medical Centre - Pulmonary, Critical Care and Sleep Medicine Division

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Reno : Sierra Nevada Cardiology Associates

Ventavis® Registry Protocol

Lebanon : Dartmouth-Hitchcock Medical Center

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Bloomfield : Michael Schwarz, MDFACC

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

New Brunswick : University of Medicine and Dentistry of New Jersey Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

New Brunswick : UMDNJ - Robert Wood Johnson Medical Center Clinical Research Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Newark : Newark Beth Isreal Medical Center-Department of Pulmonary Medicine

ACT-293987 in Pulmonary Arterial Hypertension

Newark : Pulmonary Hypertension & Lung Transplant Program Newark Beth Israel Medical Center

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Newark : Newark Beth Israel Medical Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Newark : Newark Beth Israel Medical Center

Ventavis® Registry Protocol

Lake Success : Biomedical Research Alliance of New York

Scleroderma and Pulmonary Hypertension (PHT) - Adults

New Hyde Park : Biomedical Research Alliance of New York

Pulmonary Arterial Hypertension (PAH) - Adults

Albany : Center for Rheumatology Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Bronx : Montefiore Medical Center

Ventavis® Registry Protocol

Buffalo : Kaleida Health/Buffalo General Hospital

Ventavis® Registry Protocol

Islandia : Stony Brook University Medical Center Department of Medicine

ACT-293987 in Pulmonary Arterial Hypertension

Islandia : SUNY Stony Brook University Medical Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Mineola : Winthrop Pulmonary Associates

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Mineola : Winthrop University Hospital

Ventavis® Registry Protocol

New Hyde Park : North Shore Long Island Jewish Medical Center Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

New Hyde Park : North Shore - Long Island Jewish Health System

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

New Hyde Park : North Shore University - LIJ Medical Center

Ventavis® Registry Protocol

New York : Columbia University Medical Center, Pediatric Cardiology

ACT-293987 in Pulmonary Arterial Hypertension

New York : Hospital for Special Surgery Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

New York : Cornell University Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

New York : Columbia University Medical Center Children's Hospital of New York Presbyterian - Site 9101

Pulmonary Arterial Hypertension in Children

New York : Columbia University Medical Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

New York : Beth Israel Medical Center

Ventavis® Registry Protocol

Rochester : University of Rochester

Remodulin® to Oral Treprostinil Transition

Rochester : Mary M Parkes Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Rochester : Mary M. Parkes Asthma Center, University of Rochester

The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain

Syracuse : Pulmonary Health Physicians

Ventavis® Registry Protocol

Chapel Hill : Novartis Investigative Site

An Extension Study for Patients Who Participated in the CAMN107X2201 Study

Durham : Duke University Medical Center

ACT-293987 in Pulmonary Arterial Hypertension

Pinehurst : Pinehurst Medical Clinic

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Winston Salem : Wake Forest University Phyisicans Clinic/Pulmonary

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Winston-Salem : Wake Forest University School of Medicine (Bowman Gray School of Medicine)

ACT-293987 in Pulmonary Arterial Hypertension

Cincinnati : The Lindner Clinical Trial Center

ACT-293987 in Pulmonary Arterial Hypertension

Cincinnati : University of Cincinnati

ACT-293987 in Pulmonary Arterial Hypertension

Cincinnati : University of Cincinnati Pulmonary Critical Care & Sleep Medicine

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Cincinnati : The Christ Hospital Heart & Vascular Center

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Cincinnati : University of Cincinnati

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Cincinnati : University of Cincinnati

Ventavis® Registry Protocol

Cleveland : University Hospitals of Cleveland

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Colombus : The Ohio State University Medical Center

ACT-293987 in Pulmonary Arterial Hypertension

Columbus : Davis Heart and Lung Research Institute

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Columbus : The Ohio State University Medical Center

Ventavis® Registry Protocol

Dayton : Dayton Respiratory Center

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Oklahoma City : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Bend : Heart Center Cardiology

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Portland : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Portland : Legacy Medical Group - Pulmonary Clinic Updated

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Portland : Legacy Pulmonary Northwest

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Portland : OHSU-Oregon Health and Science University

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Doylestown : Central Bucks Specialists

ACT-293987 in Pulmonary Arterial Hypertension

Doylestown : Central Bucks Specialists - The Pavilion at Doylestown Hospital

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Philadelphia : Penn Presbyterian Medical Center

ACT-293987 in Pulmonary Arterial Hypertension

Philadelphia : Pulmonary Hypertension Program, Cardiology, Children's Hospial of Philadelphia

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Philadelphia : Temple University Hospital

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Philadelphia : Pulmonary Vascular Disease Program, Penn Presbyterian Medical Center

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Philadelphia : Children's Hospital of Philadelphia

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Pittsburgh : Allegheny General Hospital

Assessmet of Patients With PAH Right Ventricular Volume

Pittsburgh : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Pittsburgh : Allegheny Singer Research Institute/Allegheny General Hospital Updated

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Pittsburgh : University of Pittsburgh Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Pittsburgh : University of Pittsburgh Medical Center

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Pittsburgh : Allegheny General Hospital

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Pittsburgh : University of Pittsburgh Medical Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Wyomissing : Respiratory Specialists

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Wyomissing : Berks Schuylkill Respiratory Specialists, Ltd.

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

York : Wellspan Lung, Sleep and Critical Care

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Providence : Rhode Island Hospital

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Providence : Rhode Island Hospital

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Charleston : Medical University of South Carolina Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Charleston : Medical University of South Carolina

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Lexington : Lexington Pulmonary and Critical Care

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Sious Falls : Sioux Falls Cardiovascular PC

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Knoxville : Statcare Pulmonary Consultants

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Knoxville : Summit Medical Group

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Nashville : Vanderbilt Medical Center

ACT-293987 in Pulmonary Arterial Hypertension

Nashville : Vanderbilt University Medical Center

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Nashville : Vanderbilt University Medical Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Dallas : UT Southwestern Medical Center at Dallas

ACT-293987 in Pulmonary Arterial Hypertension

Dallas : UT Southwestern Medical Center

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Dallas : UT Southwestern Medical Center

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Dallas : UT Southwestern Medical Center

Ventavis® Registry Protocol

El Paso : El Paso Respiratory and Sleep Consultants

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Houston : Baylor College of Medicine

ACT-293987 in Pulmonary Arterial Hypertension

Houston : University of Texas-Houston Health Center Department of Pulmonary & Critical Care

ACT-293987 in Pulmonary Arterial Hypertension

Houston : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Houston : The University of Texas Health Science Center Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Houston : Texas Children's Hospital - Department of Cardiology - Site 9107

Pulmonary Arterial Hypertension in Children

Houston : Baylor College of Medicine

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Houston : UT Health - University of Texas Houston

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Houston : Baylor College of Medicine

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Houston : Texas Children's Hospital

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Houston : University of Texas Health Science Center at Houston

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Houston : Baylore College of Medicine

Ventavis® Registry Protocol

San Antonio : University of Texas Health Science Center at San Antonio

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Provo : Central Utah Clinic

Ventavis® Registry Protocol

Salt Lake City : University of Utah Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Falls Church : IHVI, Advanced Lung Disease and Transplant Clinic

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Falls Church : Inova Fairfax Hospital

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Norfolk : Sentara Medical Group

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Norfolk : Sentara Cardiovascular Research Institute

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Norfolk : Sentara Norfolk General Hospital

Ventavis® Registry Protocol

Richmond : Virginia Commonwealth University

Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension

Seattle : Seattle Children's Hospital - Site 9106

Pulmonary Arterial Hypertension in Children

Madison : University of Wisconsin

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

Madison : University of Wisconsin Hospital-Department of Medicine

ACT-293987 in Pulmonary Arterial Hypertension

Milwaukee : St. Luke's Medical Center

ACT-293987 in Pulmonary Arterial Hypertension

Milwaukee : The Medical College of Wisconsin Updated

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Milwaukee : Aurora Health Care

Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies

Milwaukee : St. Luke's Medical Center

Ventavis® Registry Protocol

Buenos Aires : Hospital Britanico-Pneumology

ACT-293987 in Pulmonary Arterial Hypertension

Buenos Aires : Centro de Investigacion y Prevencion Cardiovascular (CIPREC)

ACT-293987 in Pulmonary Arterial Hypertension

Buenos Aires : Sanatorio Otamendi y Miroli S.A.

ACT-293987 in Pulmonary Arterial Hypertension

Buenos Aires : Sanatorio San Jose

ACT-293987 in Pulmonary Arterial Hypertension

Cordoba : Hospital Privado Centro Medico de Cordoba S.A.

ACT-293987 in Pulmonary Arterial Hypertension

Corrientes : Instituto De Cardiologia de Corrientes

ACT-293987 in Pulmonary Arterial Hypertension

Adelaide : Royal Adelaide Hospital, Cardiovascular Investigation Unit (CVIU)

ACT-293987 in Pulmonary Arterial Hypertension

Bedford Park : Flinders Medical Centre, Pulmonary Hypertension, c/- Cardiology

ACT-293987 in Pulmonary Arterial Hypertension

Chermside : Prince Charles Hospital Lung Transplant, Thoracic Department

ACT-293987 in Pulmonary Arterial Hypertension

Concord : Concord Hospital, Cardiology Department

ACT-293987 in Pulmonary Arterial Hypertension

Darlinghurst : St. Vincent's Hospital / Heart and Lung Transplant Unit

ACT-293987 in Pulmonary Arterial Hypertension

Darlinghurst : Pfizer Investigational Site

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

Darlinghurst, : Novartis Investigative Site

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients

Fitzroy : St Vincent's Hospital

ACT-293987 in Pulmonary Arterial Hypertension

Hobart : Royal Hobart Hospital, Centre for Clinical Research

ACT-293987 in Pulmonary Arterial Hypertension

New Lambton : John Hunter Hospital Autoimmune Resource and Research Centre

ACT-293987 in Pulmonary Arterial Hypertension

Parkville : Royal Melbourne Hospital, Department of Respiratory and Sleep Medicine

ACT-293987 in Pulmonary Arterial Hypertension

Parkville : Royal Children's Hospital Melbourne, Cardiology - Site 5001

Pulmonary Arterial Hypertension in Children

Perth : Royal Perth Hospital

ACT-293987 in Pulmonary Arterial Hypertension

Graz : Medizinische Universität Graz

ACT-293987 in Pulmonary Arterial Hypertension

Vienna : Medical University of Vienna and AKH Cardiology

ACT-293987 in Pulmonary Arterial Hypertension

Minsk : Minsk City Hospital No. 9

ACT-293987 in Pulmonary Arterial Hypertension

Minsk : Minsk Regional Clinical Hospital of the Red Banner of Labour

ACT-293987 in Pulmonary Arterial Hypertension

Minsk : The Republican Scientific-Practical Center "Cardiology"

ACT-293987 in Pulmonary Arterial Hypertension

Minsk : The Republican Scientific-Practical Center "Cardiology" - Site 3001

Pulmonary Arterial Hypertension in Children

Brussels : Ulb Erasme, Cardiology

ACT-293987 in Pulmonary Arterial Hypertension

Leuven : University Hospital Gasthuisberg - Pneumologie

ACT-293987 in Pulmonary Arterial Hypertension

Leuven : UZ Gasthuisberg

Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension

Leuven : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Porto Alegre : Pfizer Investigational Site

Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil

Edmonton : University of Alberta Hospital - Children's Centre

ACT-293987 in Pulmonary Arterial Hypertension

Montreal : Hopital General Juif (Jewish General Hospital)

ACT-293987 in Pulmonary Arterial Hypertension

Montreal : Sir Mortimer B Davis Jewish General Hospital

Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension

Ottawa : University of Ottawa Heart Institute

ACT-293987 in Pulmonary Arterial Hypertension

Quebec City : Institut Universitaire de Cardiologie et de Pneumologie de Quebec

ACT-293987 in Pulmonary Arterial Hypertension

Saskatoon : Royal University Hospital

ACT-293987 in Pulmonary Arterial Hypertension

Toronto : University Health Network

ACT-293987 in Pulmonary Arterial Hypertension

Toronto : University Health Network, Toronto TGH - 10 EN - 220

Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension

Vancouver : Vancouver General Hospital

ACT-293987 in Pulmonary Arterial Hypertension

Winnipeg : Health Sciences Centre

ACT-293987 in Pulmonary Arterial Hypertension

Santiago : Pontificia Universidad Catolica de Chile-Departmento De Enfermedades Cardiovasculares

ACT-293987 in Pulmonary Arterial Hypertension

Santiago : Instituto Nacional del Torax Teaching Dept

ACT-293987 in Pulmonary Arterial Hypertension

Santiago : Clinica Tabancura- Cardiology Unit

ACT-293987 in Pulmonary Arterial Hypertension

Beijing : Cardiovascular Institute & Fuwai Hospital-Pulmonary Vascular Center

ACT-293987 in Pulmonary Arterial Hypertension

Beijing : Peking Union Medical College Hospital, Rheumatology Department

ACT-293987 in Pulmonary Arterial Hypertension

Guangzhou : Guangdong General Hospital, Cardiology Department

ACT-293987 in Pulmonary Arterial Hypertension

Shanghai : Shanghai Pulmonary Hospital, Department of Pulmonary Circulation

ACT-293987 in Pulmonary Arterial Hypertension

Bogota : Fundacion Cardio Infantil

ACT-293987 in Pulmonary Arterial Hypertension

Bogota : Fundacion Clinica Shaio

ACT-293987 in Pulmonary Arterial Hypertension

Prague : Fakultní nemocnice v Motole, dětské kardiocentrum - Site 3301

Pulmonary Arterial Hypertension in Children

Praha 2 : Gen Faculty Hosp Prague Cardiology Clin

ACT-293987 in Pulmonary Arterial Hypertension

Arhus : Aarhus University Hospital , Cardiology

ACT-293987 in Pulmonary Arterial Hypertension

Copenhagen : Rigshospitalet, Hjertemedicinsk klinik - Cardiology

ACT-293987 in Pulmonary Arterial Hypertension

Bron cedex : Hosp Pradel Lyon - Dpt Pneumology

ACT-293987 in Pulmonary Arterial Hypertension

Caen : Centre Hospitalier Universitaire

Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension

Caen Cedex : Hosp Cote de Nacre - Dpt Pneumology

ACT-293987 in Pulmonary Arterial Hypertension

Clamart : Hosp A. Beclere - Dept Pulmo & Resp Intensive Care

ACT-293987 in Pulmonary Arterial Hypertension

Clamart Cedex : Hôpital Antoine Béclère

Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension

Lille : Pfizer Investigational Site

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

Lille Cedex : Hosp Huriez - Dpt Internal Medecine

ACT-293987 in Pulmonary Arterial Hypertension

Paris : Hopital Necker-Enfants Malades, Service de Cardiologie Pédiatrique - Site 2201

Pulmonary Arterial Hypertension in Children

Strasbourg : Hosp Civil - Dpt Pneumology

ACT-293987 in Pulmonary Arterial Hypertension

Toulouse : CHU de Toulouse - Hôpital des Enfants, Service de Cardiologie Pédiatrique - Site 2202

Pulmonary Arterial Hypertension in Children

Toulouse Cedex 9 : Hosp Larrey - Dpt Pneumology

ACT-293987 in Pulmonary Arterial Hypertension

Berlin : DRK Kliniken Köpenick

ACT-293987 in Pulmonary Arterial Hypertension

Berlin : Deutsches Herzzentrum Kinderkardiologie - Site 1401

Pulmonary Arterial Hypertension in Children

Coburg : Pfizer Investigational Site

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

Dresden : Universitätsklinikum Carl Gustav Carus, Medizinische Klinik1-Pneumologie/MK1-A13

ACT-293987 in Pulmonary Arterial Hypertension

Dresden : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Essen : Pfizer Investigational Site

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

Giessen : "Justus-Liebig-Universität Gießen Zentrum für Innere Medizin Medizinische Klinik II"

ACT-293987 in Pulmonary Arterial Hypertension

Giessen : Justus-Liebig-Universität Giessen, Kinderherzzentrum - Site 1403

Pulmonary Arterial Hypertension in Children

Greifswald : Universität Greifswald / Klinik für Innere Medizin B

ACT-293987 in Pulmonary Arterial Hypertension

Hamburg : Department of Respiratory Medicine, University Medical Center Hamburg-Eppendorf

Endothelial Function in Patients With Pulmonary Arterial Hypertension

Hamburg : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Hannover : Medizinische Hochschule Hannover / Klinik für Pneumologie

ACT-293987 in Pulmonary Arterial Hypertension

Hannover : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Heidelberg : Thoraxklinik am Universitätsklinikum Heidelberg

ACT-293987 in Pulmonary Arterial Hypertension

Homburg : Pfizer Investigational Site

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

Homburg : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Koln : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Köln : "Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin (Kardiologie, Pneumologie, Angiologie und Intensivmedizin)"

ACT-293987 in Pulmonary Arterial Hypertension

Leipzig : Praxis für Pneumologie und Allergologie

ACT-293987 in Pulmonary Arterial Hypertension

Löwenstein : Klinik Löwenstein gGmbH, Medizinische Klinik 1, Pneumologie - Kardiologie

ACT-293987 in Pulmonary Arterial Hypertension

Munchen : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Nuernberg : Pfizer Investigational Site

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

Regensburg : Universitätsklinkum Regensburg / Innere Medizin II

ACT-293987 in Pulmonary Arterial Hypertension

Wuerzburg : Pfizer Investigational Site

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

Wurzberg : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Alexandroupoli : University Hospital of Alexandroupoli

ACT-293987 in Pulmonary Arterial Hypertension

Athens : Onasseio Cardiosurgical Hospital

ACT-293987 in Pulmonary Arterial Hypertension

Haidari : Pfizer Investigational Site

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

Thessaloniki : University Hospital of Ahepa

ACT-293987 in Pulmonary Arterial Hypertension

Budapest : "Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály"

ACT-293987 in Pulmonary Arterial Hypertension

Budapest : "Semmelweis Egyetem, Pulmonológiai Klinika"

ACT-293987 in Pulmonary Arterial Hypertension

Budapest : Gottsegen György Országos Kardiológiai Intézet, Gyermekszív Központ, Gyermek Kardiológiai osztály - Site 3401

Pulmonary Arterial Hypertension in Children

Debrecen : Egészségügyi Járóbeteg Központ Kardiológiai Intézete - Debrecen

ACT-293987 in Pulmonary Arterial Hypertension

Pécs : "Pécsi Tudományegyetem Klinikai Központ,

ACT-293987 in Pulmonary Arterial Hypertension

Szeged : "Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ, II. sz. Belgyógyászati klinika és Kardiológiai központ"

ACT-293987 in Pulmonary Arterial Hypertension

Szeged : Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ, Gyermekgyógyászati Klinika és Gyermekegészségügyi Központ - Site 3402

Pulmonary Arterial Hypertension in Children

Ahmedabad : Sanjivani Hospitals - Department of Cardiology

ACT-293987 in Pulmonary Arterial Hypertension

Chennai : Apollo Hospitals, Chennai

ACT-293987 in Pulmonary Arterial Hypertension

Chennai : Frontier Lifeline Hospitals, Dr KM Cherian Heart Foundation, Chennai

ACT-293987 in Pulmonary Arterial Hypertension

Hyderabad : Pfizer Investigational Site

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

Hyderabad : CARE Hospitals Nampally, Cardiology Dep. Hyderabad

ACT-293987 in Pulmonary Arterial Hypertension

Hyderabad : CARE Hospitals, Cardiology Dep. Hyderabad - Site 5302

Pulmonary Arterial Hypertension in Children

Kochi : Pfizer Investigational Site

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

New Dehli : Indraprashta Apollo Hospitals, Pediatric Cardiology - Site 5303

Pulmonary Arterial Hypertension in Children

New Delhi : Apollo Indraprastha Hospitals

ACT-293987 in Pulmonary Arterial Hypertension

Dublin : Mater Miscordiae University Hospital

ACT-293987 in Pulmonary Arterial Hypertension

Haifa : Department of Cardiology, Rambam Medical Center

Measuring Blood Pressure in the Lung Circulation With Sonar Technology (Echo-Doppler)

Jerusalem : Pulmonology Institute, Hadassah University Hospital at Ein Karem

ACT-293987 in Pulmonary Arterial Hypertension

Petach Tikvah : Rabin Medical Centre - Pulmonology

ACT-293987 in Pulmonary Arterial Hypertension

Petach Tikvah : Schneider Children's Medical Center- Institute of pediatric cardiology - Site 7101

Pulmonary Arterial Hypertension in Children

Rehovot : Kaplan Medical - Pulmonary Institute

ACT-293987 in Pulmonary Arterial Hypertension

Tel-Hashomer : The Chaim Sheba Med Ctr -Pulmonology

ACT-293987 in Pulmonary Arterial Hypertension

Bologna : Policlinico S. Orsola-Malpighi - Dipartimento Cardio-Toraco-Vascolare

ACT-293987 in Pulmonary Arterial Hypertension

Bologna : Orsola Malpighi

Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension

Napoli : Seconda Università Degli Studi di Napoli - Azienda Universitaria Policlinico - Dipartimento Assistenziale di medicina Generale, Angiologia, Endocrinologia, Epatogastroenterologia e Reumatologia - Unità Operativa di Reumatologia

ACT-293987 in Pulmonary Arterial Hypertension

Napoli : Ospedale Monaldi - Dipartimento di Cardiologia - Unità Operativa Complessa di Cardiologia - Adulti Sun

ACT-293987 in Pulmonary Arterial Hypertension

Padova : Università Degli Studi di Padova - Dipartimento di Pediatria - Servizio di Cardiologia Pediatrica - Site 1501

Pulmonary Arterial Hypertension in Children

Palermo : ISMETT - Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione - Dipartimento di Medicina - Divisione di Pneumologia

ACT-293987 in Pulmonary Arterial Hypertension

Rome : Novartis Investigative Site

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Rome : Novartis Investigative Site

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients

Rome : Ospedale Pediatrico "Bambino Gesù" - Dipartimento Medico Chirurgico di Cardiologia Pediatrica - Site 1502

Pulmonary Arterial Hypertension in Children

Kayama : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Miyagi : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Shizuoka : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Tokyo : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Incheon : Gil Medical Centre

ACT-293987 in Pulmonary Arterial Hypertension

Seoul : Yonsei University Health System Dept of Cardiology

ACT-293987 in Pulmonary Arterial Hypertension

Seoul : Seoul Nathional University Hospital

ACT-293987 in Pulmonary Arterial Hypertension

Seoul : Samsung Medical Center, Division of Cardiology

ACT-293987 in Pulmonary Arterial Hypertension

Seoul : "The Catholic University of Korea, Seoul St. Mary's Hospital Department of Cardiology"

ACT-293987 in Pulmonary Arterial Hypertension

Seoul : Seoul National University Hospital

Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)

Seoul : Samsung Medical Center

Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)

Seoul : Novartis Investigative Site

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension

Special City of Seoul : Severance Hospital, Yonsei University Health System

Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)

Kuala Lumpur : Institut Jantung Negara (National Heart Institute)

ACT-293987 in Pulmonary Arterial Hypertension

Mexico City : Instituto Nacional de Cardiologia (INC) Ignacio Chavez

ACT-293987 in Pulmonary Arterial Hypertension

Mexico City : Instituto Nacional de Cardiologia (INC) Ignacio Chavez - Site 8401

Pulmonary Arterial Hypertension in Children

Mexico D.F. : Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubrian

ACT-293987 in Pulmonary Arterial Hypertension

Amsterdam : VU Medisch Centrum / Afdeling longziekten, secretariaat 4A 48

ACT-293987 in Pulmonary Arterial Hypertension

Amsterdam : VU Medisch Centrum (VUMC)

Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension

Groningen : Universitair Medish Centrum Groningen, Kindercardiologie - Site 1601

Pulmonary Arterial Hypertension in Children

Maastricht : Academisch Ziekenhuis Maastricht / Department of Pulmonary Diseases

ACT-293987 in Pulmonary Arterial Hypertension

Nieuwegein : St. Antonius Ziekenhuis afdeling Longziekten

ACT-293987 in Pulmonary Arterial Hypertension

Rotterdam : Erasmus Medisch Centrum Rotterdam afdeling longziekten

ACT-293987 in Pulmonary Arterial Hypertension

Lima : Hospital Nacional Edgardo Rebagliati / Unidad de Investigacion Cardiologia 2

ACT-293987 in Pulmonary Arterial Hypertension

Lima : Instituto de Enfermedades Respiratorias Clinica San Gabriel

ACT-293987 in Pulmonary Arterial Hypertension

Gdansk : Uniwersyteckie Centrum Kliniczne Klinika Kardiologii Dziecięcej i Wad Wrodzonych Serca - Site 3604

Pulmonary Arterial Hypertension in Children

Gdańsk : "Uniwersyteckie Centrum Kliniczne II Klinika Kardiologii i Elektroterapii Serca"

ACT-293987 in Pulmonary Arterial Hypertension

Krakow : "Instytut Kardiologii Collegium Medium UJ Krakowski Szpital Specjalistyczny im Jana Pawła II Klinika Chorób Serca i Naczyń"

ACT-293987 in Pulmonary Arterial Hypertension

Łódź : "Wojewódzki Specjalistyczny Szpital im. dr Władysława Biegańskiego Oddział Kardiologiczny, II Katedra i Klinika Kardiologii UM"

ACT-293987 in Pulmonary Arterial Hypertension

Many Locations : Updated

Efficacy of Ventavis Used in Real-life Setting.

Warszawa : "Instytut Gruźlicy i Chorób Płuc Klinika Chorób Wewnętrznych Klatki Piersiowej"

ACT-293987 in Pulmonary Arterial Hypertension

Warszawa : Instytut Pomnik - Centrum Zdrowia Dziecka Klinika Kardiologii Dziecięcej - Site 3601

Pulmonary Arterial Hypertension in Children

Wroclaw : Wojewódzki Szpital Specjalistyczny we Wrocławiu Oddział Kardiologii Dziecięcej z pododdziałem Intensywnego Nadzoru Kardiologicznego - Site 3605

Pulmonary Arterial Hypertension in Children

San Juan : PAH Clinic CPR at Auxilio Mutuo

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Bucharest : "Institutul de Pneumologie "Marius Nasta", I. Clinica de Pneumoftiziologie"

ACT-293987 in Pulmonary Arterial Hypertension

Iasi : "Spitalul Clinic de Pneumoftiziologie Iasi Sectia Clinica I de Pneumoftiziologie"

ACT-293987 in Pulmonary Arterial Hypertension

Barnaul : Municipal Medical Institution City Hospital #5

ACT-293987 in Pulmonary Arterial Hypertension

Ekaterinburg : Regional Clinical Hospital # 1

ACT-293987 in Pulmonary Arterial Hypertension

Kemerovo : Kemerovo Cardiology Dispensary / Kemerovo Regional Hospital

ACT-293987 in Pulmonary Arterial Hypertension

Kemerovo : RAMS Institution, Research Institute for complex issues of cardiovascular diseases, Siberian branch of the Russian Academy of Medical Sciences - Site 3805

Pulmonary Arterial Hypertension in Children

Moscow : The Institution of the Clinical Cardiology named after A. L. Myaskinov

ACT-293987 in Pulmonary Arterial Hypertension

Moscow : Scientific Research Institute of Pulmonology of the Federal Medical and Biological Agency of Russia

ACT-293987 in Pulmonary Arterial Hypertension

Moscow : State Institution, "Institute fo Rheumatology of RAMS"

ACT-293987 in Pulmonary Arterial Hypertension

Moscow : Scientific Center of Cardiovascular Surgery named after A.N.Bakulev of the RAMS - Site 3803

Pulmonary Arterial Hypertension in Children

Moscow : Moscow Scientific Research Institute for Pediatrics and Childrens Surgery of Rosmedtechnologies - Site 3804

Pulmonary Arterial Hypertension in Children

Novosibirsk : State Institution "Scientific Research Institute of clinical and experimental Lymphology of RAMS, Siberian branch"

ACT-293987 in Pulmonary Arterial Hypertension

St Petersburg : V. A. Almazov Institute of Cardiology, Russian Ministry of Healthcare and Social Development / Medical Treatment and Rehabilitation Complex

ACT-293987 in Pulmonary Arterial Hypertension

St. Petersberg : Federal State Institution "Federal center of Heart, Blood and Endocrinology named after V.A.Almazov Rosmedtekhnologies" - Site 3802

Pulmonary Arterial Hypertension in Children

St. Petersburg : State Educational Institution of Higher Professional Education "Saint Petersburg State Pediatric Medical Academy of Roszdrav" - Site 3801

Pulmonary Arterial Hypertension in Children

Tomsk : Tomsk Regional Clinical Hospital/ Pulmonology Unit

ACT-293987 in Pulmonary Arterial Hypertension

Tomsk : Cardiology Scientific Research Institute of Tomsk Scientific Center of RAMs, Siberian Branch / Cardiovascular Surgery Department

ACT-293987 in Pulmonary Arterial Hypertension

Belgrade : "Klinički Centar Srbije, Klinika za pulmologiju"

ACT-293987 in Pulmonary Arterial Hypertension

Belgrade : "Kliničko-bolnički centar Zemun, Kardiološko odeljenje"

ACT-293987 in Pulmonary Arterial Hypertension

Belgrade : Institut za zdravstvenu zaštitu majke i deteta Srbije "Dr Vukan Čupić", Služba za ispitivanje i lečenje bolesti srca i krvnih sudova - Site 3902

Pulmonary Arterial Hypertension in Children

Belgrade : Univerzitetska dečja klinika, Služba za kardiologiju - Site 3901

Pulmonary Arterial Hypertension in Children

Singapore : National Heart Centre (NHC) Singapore

ACT-293987 in Pulmonary Arterial Hypertension

Bratislava : Národný ústav srdcových a cievnych chorôb, a.s. - NÚSCH a.s.

ACT-293987 in Pulmonary Arterial Hypertension

Košice : Východoslovenský ústav srdcových a cievnych chorôb, a.s., Kardiologické oddelenie

ACT-293987 in Pulmonary Arterial Hypertension

Durban : Paediatric Cardiology Albert Luthuli Central Hospital - Site 6003

Pulmonary Arterial Hypertension in Children

Pretoria : Division of Paediatric Cardiology, Steve Biko Academic Hospital - Site 6002

Pulmonary Arterial Hypertension in Children

Barcelona : Clinic-Barcelona

ACT-293987 in Pulmonary Arterial Hypertension

Barcelona : Hosp Vall D'Hebron - Barcelona - Pneumology

ACT-293987 in Pulmonary Arterial Hypertension

Barcelona : Hospital Vall d'Hebron

Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension

Madrid : Hospital 12 Octubre

ACT-293987 in Pulmonary Arterial Hypertension

Many Locations : Updated

Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System

Goteborg : Sahlgrenska Universitetssjukhuset, Kardiologi

ACT-293987 in Pulmonary Arterial Hypertension

Linköping : Linköping University Hospital, Cardiology

ACT-293987 in Pulmonary Arterial Hypertension

Umea : Umeå University Hospital, Cardiology (Umeå)

ACT-293987 in Pulmonary Arterial Hypertension

Uppsala : Uppsala Akademiska Sjukhuset, Kardiologkliniken 50F

ACT-293987 in Pulmonary Arterial Hypertension

Basel : University Hospital Basel Division of Pneumology

ACT-293987 in Pulmonary Arterial Hypertension

Bern : Universitätsspital Bern, Clinic for Pneumology (Inselspital)

ACT-293987 in Pulmonary Arterial Hypertension